Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
about
Treatment in canine epilepsy--a systematic reviewAntiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogsThe use of imepitoin (Pexion™) on fear and anxiety related problems in dogs - a case series.The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy.Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsyExperimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs.Imepitoin as novel treatment option for canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism in dogs.International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in EuropeEfficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up.Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy.Canine epilepsy as a translational model?Canine epilepsy: an underutilized model.Canine versus human epilepsy: are we up to date?2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs.Add-on treatment with verapamil in pharmacoresistant canine epilepsy.Epilepsy after head injury in dogs: a natural model of posttraumatic epilepsy.
P2860
Q27012923-3EDDC0B1-4270-4B48-8201-1C1AE7A7F0ECQ28071335-CF1AE001-A37C-4E9F-85A0-C519671290BEQ30855710-FA5F4218-00F8-49A1-A608-6B2599AE427BQ34393213-927CEAA6-CD88-45ED-90AE-A7E6236ED639Q34554961-FD19213C-1113-4DD8-A493-358C0DDB058CQ34559174-EEE711AA-4BF5-43C7-A671-973D22D7E80EQ34795269-0813DC58-B096-46C1-B620-952AE3812E23Q35758344-1B99A4B1-13ED-41A8-9455-8BE9A6BCE7D5Q35761727-B41DE2A6-83FD-448C-825F-064D8DD8654AQ36259058-0E694028-C1FF-499E-8326-2D684E840C27Q38090658-E749A429-E13E-40EB-AED4-8D2240EF0D05Q38220810-6B21ADF4-1D72-4688-867F-5CD9193FADA9Q38756758-4DC66147-2277-49F7-ADDA-272B53849D50Q38905308-2430174F-4162-4DC6-B3BC-35568C4C5C82Q44982064-A6C80D1A-4603-408E-9B07-C893669B17E9Q48223148-3E08E653-C02E-4A75-B97F-20C1CBE733E6
P2860
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@ast
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@en
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@nl
type
label
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@ast
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@en
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@nl
prefLabel
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@ast
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@en
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@nl
P2093
P2860
P1433
P1476
Anticonvulsant efficacy of the ...... ntaneously recurrent seizures.
@en
P2093
Chris Rundfeldt
Heidrun Potschka
Susanne Rieck
Wolfgang Löscher
P2860
P304
P356
10.1111/J.0013-9580.2004.21204.X
P577
2004-10-01T00:00:00Z